Post Content
Adagene Inc. (NASDAQ:ADAG) is one of the
10 Unstoppable Stocks That Could Double Your Money.
Adagene Inc. (NASDAQ:ADAG) is one of the unstoppable stocks that could double your money. On April 2, Adagene announced a clinical collaboration with Incyte Corp. (NASDAQ:INCY) to evaluate a novel combination therapy for microsatellite stable colorectal cancer/MSS CRC. The study will combine Adagene’s muzastotug/ADG126, which is a masked anti-CTLA-4 SAFEbody, with Incyte’s INCA33890, a bispecific antibody targeting TGFβR2 and PD-1.
This Phase 1 trial, expected to begin in 2026, will focus on third-line patients both with and without liver metastases, a group that typically faces a poor prognosis and limited response to standard immunotherapies. The collaboration uses muzastotug’s potential as a backbone therapy, designed to increase the therapeutic index by selectively activating in the tumor microenvironment. While Incyte will sponsor and conduct the trial, Adagene will provide the clinical supply of muzastotug.
Photo by National Cancer Institute on Unsplash
This marks a significant expansion of muzastotug’s clinical portfolio, which already includes promising data in combination with pembrolizumab, where it achieved a 31% overall response rate in specific high-dose cohorts for late-line MSS CRC patients. Additionally, Adagene Inc. (NASDAQ:ADAG) recently released updated data from its ongoing Phase 1b/2 study, showing that muzastotug in combination with pembrolizumab achieved a median overall survival of 19.8 months in the 10 mg/kg cohorts.
Adagene Inc. (NASDAQ:ADAG) is a biotechnology company that specializes in monoclonal antibody drugs for cancers. The company’s diverse pipeline of clinical & preclinical oncology candidates includes its lead anti-CTLA-4 antibody ADG126 and various mAb & bispecific programs.
While we acknowledge the potential of ADAG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.